List view / Grid view

Articles

NGS: enabling biomarker discovery at single-cell resolution

12 September 2018 | By

Investigations using Next-Generation Sequencing (NGS), once the domain of well-funded labs, have now become mainstream in the hunt for biomarkers for various disorders – ranging from breast and colon cancers to cardiomyopathies, diabetes, congenital cataracts, liver diseases and mitochondrial disorders. The NHS Executive (NHSE) has recently announced the use of…

Expert view: Challenges in flow cytometry

11 September 2018 | By

Flow cytometry is a powerful and flexible technology that delivers high content information from single cells and particles. Flow cytometry lends itself to a wide variety of applications, but traditional flow cytometry technologies are not widely adopted in the drug discovery industry due to limited throughput, slow sampling speeds and…

Upstream Bioprocessing In-Depth Focus 2018

10 September 2018 | By

In this In-Depth Focus: upstream cell culture processes for the production of therapeutic proteins, the evolving role of three-dimensional in-vitro cell culture techniques in drug discovery, and human iPSCs-derived functional cells are revolutionising phenotypic drug discovery and development.

Flow Cytometry In-Depth Focus 2018

7 September 2018 | By

Flow cytometry has played a key role in drug development, largely due to its ability to measure up to twenty parameters on single cells or particles suspended in a fluid stream. Conor Fitzpatrick discusses how the rise of high-throughput flow cytometry has contributed to the advancements in drug discovery...

NGS: hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of human genetic diseases

7 September 2018 | By

Next generation sequencing (NGS) has revolutionised genomics research providing a wealth of genetic information of immense value to researchers. NGS technologies have been evolving over the last decade, leading to substantial improvement in understanding different biological systems from broader and deeper perspectives.1

Expert view: Multiplexed screens in biologics discovery

7 September 2018 | By

Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anti-cancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy and bispecific T-cell engagers. While these approaches use different tactics to attack tumours, they often employ monoclonal antibodies to target…